Cargando…
Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status
Professional phagocytic cells, such as dendritic cells, are mainly responsible for phagocytosis, antigen presentation, and cytokine secretion, which induce subsequent activation of T cell-mediated immunity. Thus, strategies that deliver antigens and stimulatory signals to the cells have significant...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810488/ https://www.ncbi.nlm.nih.gov/pubmed/24224170 http://dx.doi.org/10.1155/2013/562924 |
_version_ | 1782288795224244224 |
---|---|
author | Kojima, Naoya Ishii, Mariko Kawauchi, Yoko Takagi, Hideaki |
author_facet | Kojima, Naoya Ishii, Mariko Kawauchi, Yoko Takagi, Hideaki |
author_sort | Kojima, Naoya |
collection | PubMed |
description | Professional phagocytic cells, such as dendritic cells, are mainly responsible for phagocytosis, antigen presentation, and cytokine secretion, which induce subsequent activation of T cell-mediated immunity. Thus, strategies that deliver antigens and stimulatory signals to the cells have significant implications for vaccine design. In this paper, we summarize the potential for liposomes coated with the neoglycolipids containing oligomannose residues (OMLs) as a novel adjuvant for induction of Th1 immune responses and CTLs specific for the encased antigen. OMLs preferentially take up peripheral phagocytic cells. In response to OML uptake, the cells secrete IL-12 selectively, enhance the expression of costimulatory molecules, and migrate into lymphoid tissues from peripheral tissues. OMLs also have the ability to deliver encapsulated protein antigens to the MHC class I and class II pathways to generate antigen-specific CTLs and Th1 cells, respectively, and lipid antigen to CD1d to activate NKT cells. Since administration of OML-based vaccines can eliminate an established tumor, inhibit elevation of the serum IgE level, and prevent progression of protozoan infections in several murine, human, and bovine models, OML-based vaccines have revealed their potential for clinical use in vaccination for a variety of diseases in which CTLs and/or Th1 cells act as effector cells. |
format | Online Article Text |
id | pubmed-3810488 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-38104882013-11-10 Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status Kojima, Naoya Ishii, Mariko Kawauchi, Yoko Takagi, Hideaki Biomed Res Int Review Article Professional phagocytic cells, such as dendritic cells, are mainly responsible for phagocytosis, antigen presentation, and cytokine secretion, which induce subsequent activation of T cell-mediated immunity. Thus, strategies that deliver antigens and stimulatory signals to the cells have significant implications for vaccine design. In this paper, we summarize the potential for liposomes coated with the neoglycolipids containing oligomannose residues (OMLs) as a novel adjuvant for induction of Th1 immune responses and CTLs specific for the encased antigen. OMLs preferentially take up peripheral phagocytic cells. In response to OML uptake, the cells secrete IL-12 selectively, enhance the expression of costimulatory molecules, and migrate into lymphoid tissues from peripheral tissues. OMLs also have the ability to deliver encapsulated protein antigens to the MHC class I and class II pathways to generate antigen-specific CTLs and Th1 cells, respectively, and lipid antigen to CD1d to activate NKT cells. Since administration of OML-based vaccines can eliminate an established tumor, inhibit elevation of the serum IgE level, and prevent progression of protozoan infections in several murine, human, and bovine models, OML-based vaccines have revealed their potential for clinical use in vaccination for a variety of diseases in which CTLs and/or Th1 cells act as effector cells. Hindawi Publishing Corporation 2013 2013-10-10 /pmc/articles/PMC3810488/ /pubmed/24224170 http://dx.doi.org/10.1155/2013/562924 Text en Copyright © 2013 Naoya Kojima et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Kojima, Naoya Ishii, Mariko Kawauchi, Yoko Takagi, Hideaki Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status |
title | Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status |
title_full | Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status |
title_fullStr | Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status |
title_full_unstemmed | Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status |
title_short | Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status |
title_sort | oligomannose-coated liposome as a novel adjuvant for the induction of cellular immune responses to control disease status |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810488/ https://www.ncbi.nlm.nih.gov/pubmed/24224170 http://dx.doi.org/10.1155/2013/562924 |
work_keys_str_mv | AT kojimanaoya oligomannosecoatedliposomeasanoveladjuvantfortheinductionofcellularimmuneresponsestocontroldiseasestatus AT ishiimariko oligomannosecoatedliposomeasanoveladjuvantfortheinductionofcellularimmuneresponsestocontroldiseasestatus AT kawauchiyoko oligomannosecoatedliposomeasanoveladjuvantfortheinductionofcellularimmuneresponsestocontroldiseasestatus AT takagihideaki oligomannosecoatedliposomeasanoveladjuvantfortheinductionofcellularimmuneresponsestocontroldiseasestatus |